The regulation of COVID-19 clinical trials in Peru
Keywords:COVID-19, Clinical Trials as Topic, Coronavirus Infections, Peru, Government Regulation
AbstractCOVID-19 has affected the conduct of clinical trials worldwide. Once the health emergency began in Peru, the national government took measures to guarantee the conduct of COVID-19 clinical trials. A national research ethics committee was exclusively established for COVID-19 clinical trials; and a regulatory framework was implemented to ensure the ethical and timely conduct of these studies. To december 31, 2020, the Peruvian National Health Institute authorized 29 clinical trials, of which 4 test vaccines. The mean and standard deviation of time authorization were 19.3 and 10.5 days, respectively. 58.6% (n= 17) were phase II clinical trials and 34.5% (n= 10) were phase III; 31.0% (n= 9) were sponsored by a Peruvian institution. The aim of the actions implemented was to promote COVID-19 research while responding to the health emergency needs without affecting the protection of participants or the rigor of the studies.
Download data is not yet available.
How to Cite
Cahuina Lope P, Carracedo S, Romani F. The regulation of COVID-19 clinical trials in Peru. Rev Peru Med Exp Salud Publica [nternet]. 2021 Feb. 10 [cited 2023 May 31];38(1):171-7. vailable from: https://rpmesp.ins.gob.pe/index.php/rpmesp/article/view/6627
Copyright (c) 2021 Revista Peruana de Medicina Experimental y Salud Pública
This work is licensed under a Creative Commons Attribution 4.0 International License.